Skip to content

4564.T

OncoTherapy Science,Inc.

グロース · 医薬品 · 医薬品 · JP

JPY 17.00
−5.56%
Ask drillr

Income statement

MetricTTM2026202520242023
Revenue
Total Revenue784.0M808.0M750.0M610.0M1.1B
Cost of Revenue755.7M794.6M762.8M787.8M1.1B
Gross Profit28.3M13.4M(12.8M)(177.8M)40.8M
Operating Expenses
R&D Expense—————
SG&A Expense307.0M289.4M294.1M265.0M431.6M
General & Admin Expense—————
Selling & Marketing Expense—————
Other Expenses—————
Total Operating Expenses307.0M289.4M294.1M265.0M431.6M
Cost and Expenses1.6B1.6B1.5B1.7B2.2B
Operating Income (EBIT)(793.0M)(810.0M)(797.0M)(1.1B)(1.1B)
Non-Operating
Interest Income—————
Interest Expense1.3M1.3M1.2M218.0K—
Net Interest Income—————
Other Non-Op Income/Expense(24.7M)(35.4M)(17.1M)(15.6M)(26.7M)
Non-Operating Income (excl Interest)446.0K—50.0K6.0K357.0K
EBT (Pre-Tax Income)(879.5M)(908.5M)(813.1M)(1.3B)(1.1B)
Income Tax Expense2.2M2.2M2.2M2.4M2.2M
Bottom Line
Net Income(881.0M)(910.0M)(815.0M)(1.3B)(1.1B)
Earnings from Cont. Ops—————
Earnings from Discont. Ops—————
Bottom Line Net Income(881.0M)(910.0M)(815.0M)(1.3B)(1.1B)
Per Share
Basic EPS(¥3)(¥3)(¥3)(¥6)(¥6)
Diluted EPS(¥3)(¥3)———
Revenue Per Share¥3¥2¥3¥3¥6
Shares
Basic Shares Outstanding311.0M328.2M261.1M212.8M192.6M
Diluted Shares Outstanding—————
Profitability Metrics
EBITDA—————
D&A—————
EBIT(793.0M)(810.0M)(797.0M)(1.1B)(1.1B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026